Sarah Arron’s Post

#HighlyCitedPapers 📝 Gene Expression Profiling in Early Breast Cancer—Patient Stratification Based on Molecular and Tumor Microenvironment Features — Munkácsy et al. In this paper, the authors aimed to evaluate the current evidence of using #gene expression signatures or profiling (GEP) in clinic and explore and discuss the increasing importance of immune parameters and the possibility to refine current tools with additional immune-GEPs that may help to refine prognosis and provide better predictive tools for early-stage breast #cancer. Full text is available 👇 https://lnkd.in/dxvmVf2x #medicine #health #research #science

There is still time to register for our upcoming webinar: "Development of #digitalPCR-based products to test for cancer-related gene mutations in cancer tissue and liquid biopsies." Sign up to learn more about how IDT is playing a critical role in transforming cancer mutation research: https://bit.ly/4eUw2YA

Highly recommend this deep dive series on major translational themes at this year's American Society of Gene & Cell Therapy meeting from my BioCentury Inc. colleagues Lauren Martz and Danielle Golovin, Ph.D. : CAR Ts outside of cancer (and even outside autoimmunity!), epigenetic editor durability, vectorized mAbs, blood-brain barrier crossing technologies, and more. https://lnkd.in/gmaFDith

TP53 Variants: The Ticking Time Bomb in Your Gene TP53, a powerful tumor suppressor gene, can harbor both germline and somatic variants. Understanding the significance of these variants is crucial for accurate diagnosis and personalized treatment. This study explores the nuances of TP53 testing and the challenges faced by healthcare providers in interpreting these results. Details: https://lnkd.in/gfCZ8ZZy  #genetics #cancer #oncology #hematology #NGS #TP53 #healthcare #medicalresearch #precisionmedicine

Discover how integrating spatial transcriptomics (ST) and bulk RNA-Seq provides unprecedented insights into the tumor microenvironment of non-small cell lung cancer (NSCLC). This study reveals the power of these techniques in understanding gene expression profiles, refining target expression by cell type, and identifying variability within tumors. Download our poster to learn more about this innovative approach and its potential for personalized therapeutic strategies. https://hubs.la/Q02zQzhl0 #NSCLC #SpatialTranscriptomics #RNASeq #PersonalizedMedicine

Discover the Cutting-Edge of cancer research: Dive into our detailed poster on Spatial Transcriptomics and learn how these groundbreaking technologies are revolutionizing our understanding of NSCLC. #CancerResearch #NSCLC #SpatialTranscriptomics #RNAseq #LearnMore

A study from the lab of Tulane's Dr. Toraih explores the role of long non-coding RNAs (lncRNAs) in ovarian #cancer (OC), highlighting their potential as biomarkers for early detection and prognosis. Analysis of specific genetic variants like MALAT1 and MIAT could help in understanding their influence on OC risk and progression. #TulaneResearch #Medicine Read the paper in the comments! Image: Frequency of different variants of one of the studied lncRNAs, MIAT. Individuals carry two copies of the gene, and each copy can have either the C or T form. Malignant tumors were more likely to be from individuals with two copies of the C form of the gene, suggesting that the T form may be protective.

Co-expression Analysis of lncRNA and mRNA in Spinal Cord Astrocytoma, Insights on Gene Length and Functional Implications The co-expression analysis of long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) in spinal cord astrocytoma has provided critical insights into the differential characteristics and potential functions of these molecules. By identifying similar genes expressed in both lncRNAs and mRNAs, the analysis highlights their functional interconnections, with implications for understanding the tumor biology of spinal cord astrocytoma.

It seems that genetic mutations are not essential to the initiation of cancer. Temporary epigenetic dysregulation can mediate permanent changes that can drive tumour initiation and progression, and even different cell behaviours within tumours. Epigenetic events might thus play a major role at early stages of oncogenesis or during tumour progression in some mammalian cancers, underscoring the need to understand both the genetic and epigenetic landscapes of tumours. This will have implications for future clinical approaches to personalized diagnostics and treatment. https://lnkd.in/dARq9meb